| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050012644 |
| P356 | DOI | 10.1186/1757-2215-6-42 |
| P932 | PMC publication ID | 3707788 |
| P698 | PubMed publication ID | 23809664 |
| P5875 | ResearchGate publication ID | 243965854 |
| P50 | author | Sandrina Lambrechts | Q38299962 |
| Robert Zeillinger | Q39409373 | ||
| Jalid Sehouli | Q40942564 | ||
| Dan Cacsire Castillo-Tong | Q40944620 | ||
| Ignace Vergote | Q89808263 | ||
| P2093 | author name string | Nicole Concin | |
| Ioana Braicu | |||
| Sven Mahner | |||
| Paul Speiser | |||
| Christine Eulenburg | |||
| Linn Woelber | |||
| Radoslav Chekerov | |||
| Fabian Trillsch | |||
| Alain Zeimet | |||
| Els van Nieuwenhuysen | |||
| P2860 | cites work | Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data | Q34135353 |
| Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials | Q35125943 | ||
| Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly | Q35214119 | ||
| A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis | Q36095955 | ||
| Ovarian cancer in younger vs older women: a population-based analysis | Q36611969 | ||
| Comprehensive geriatric assessment for older patients with cancer | Q36815525 | ||
| Older female cancer patients: importance, causes, and consequences of undertreatment | Q36815538 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review | Q37432638 | ||
| High-risk surgery: epidemiology and outcomes. | Q37759971 | ||
| Clinical trials and treatment of the elderly diagnosed with ovarian cancer | Q37872171 | ||
| Cancer in older persons: an international issue in an aging world | Q40514555 | ||
| Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients | Q43517056 | ||
| Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study | Q44049941 | ||
| EORTC elderly task force position paper: approach to the older cancer patient | Q44084117 | ||
| Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience | Q45239421 | ||
| Impact of advancing age on abdominal surgical outcomes | Q50174006 | ||
| Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium | Q61853673 | ||
| Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
| Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany | Q79326663 | ||
| Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study | Q80205167 | ||
| Surgical care of elderly women with ovarian cancer: a population-based perspective | Q80961917 | ||
| The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study | Q81574365 | ||
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial | Q83287534 | ||
| Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer | Q84270399 | ||
| Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience | Q84962933 | ||
| P433 | issue | 1 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 42 | |
| P577 | publication date | 2013-06-28 | |
| P1433 | published in | Journal of Ovarian Research | Q27721898 |
| P1476 | title | Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium | |
| P478 | volume | 6 |
| Q40984871 | Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis |
| Q33792167 | Age is associated with prognosis in serous ovarian carcinoma |
| Q55074255 | Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue. |
| Q41226857 | Chemotherapy for Elderly Ovarian Cancer Patients |
| Q92578659 | Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years |
| Q90198413 | Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age |
| Q38963512 | Improving outcomes for older women with gynaecological malignancies |
| Q39827859 | Non-surgical management of ovarian cancer: Prevalence and implications |
| Q36861215 | Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study |
| Q47146551 | Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer. |
| Q36645950 | Role of Surgery in the Elderly Patients Affected from Advanced Stage Ovarian Cancer |
| Q51312590 | Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. |
| Q26751608 | The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years |
| Q36918911 | Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin |
| Q50420488 | Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis |
| Q64921196 | With Great Age Comes Great Metastatic Ability: Ovarian Cancer and the Appeal of the Aging Peritoneal Microenvironment. |
Search more.